SNY

Sanofi ADS
D

SNY

Arincen75/100B

Sanofi ADS P/E ratio

Sanofi ADS's P/E ratio is 71.48: its share price of 47.01 over its earnings per share of 0.66 over the last twelve months.

Today
71.48
Forward P/E, next 12 months
9.71
PEG ratio
4.19
Median, 5 years
17.90
Low, 5 years
10.08
High, 5 years
83.08

P/E ratio = price ÷ EPS (last 12 months) = 47.01 ÷ 0.66 = 71.48

Each day's closing price over the earnings per share of the last four quarters reported by that day (basic EPS, adjusted for splits). The P/E moves with the price every day and with the earnings at each report.

The forward P/E divides the price by the analysts' average EPS estimate for the next twelve months: the fiscal year in progress for the months left in it, the next one for the rest. For past days it uses each year's latest estimate, as the estimates of the time were not recorded (we keep a daily copy from November 2026), so the past line reads the price against the earnings expected by the time each year was reported.

Is Sanofi ADS's P/E high compared with its own history?

Sanofi ADS's P/E of 71.5 is near the top of its 5-year range (10.1 to 83.1, median 17.9). Analysts expect faster growth than in recent years, which can explain part of the high P/E.

Is the price fair? See the whole check

A P/E is compared with the stock's own last five years, not with other companies. Why the market pays more or less (news, rates, the sector) is not in these figures.

P/E ratio by year and by quarter

Fiscal yearPeriod endingP/E ratioForward P/EMarket capNet income
FY2027 · Estimate31 Dec 20279.62———
FY2026 · Estimate31 Dec 202610.25———
Today71.489.71101.54B3.96B
FY202531 Dec 202518.0610.04100.67B5.57B
FY202431 Dec 202421.2112.08116.57B5.50B
FY202331 Dec 202322.2512.19112.63B5.06B
FY202231 Dec 202214.2111.25113.24B7.97B
FY202131 Dec 202117.7410.75110.37B6.22B
FY202031 Dec 20208.0913.1899.68B12.31B
FY201931 Dec 201960.2613.18111.90B1.86B
FY201831 Dec 201821.9313.1894.41B4.31B
FY201731 Dec 201710.6813.1890.04B8.43B
FY201631 Dec 201620.9813.1198.82B4.71B
FY201531 Dec 201523.9313.85102.59B4.29B
FY201431 Dec 201422.59—99.18B4.39B
FY201331 Dec 201327.76—103.17B3.72B
FY201231 Dec 201219.08—94.75B4.97B
FY201131 Dec 201113.09—74.54B5.69B
FY201031 Dec 201011.49—62.84B5.47B
FY200931 Dec 200913.60—71.60B5.27B
FY200831 Dec 200815.66—60.31B3.85B
FY200731 Dec 200715.94—84.03B5.27B
FY200631 Dec 200623.52—94.23B4.01B
FY200531 Dec 200543.89—99.02B2.26B
FY200431 Dec 2004——53.80B-3.61B
FY200331 Dec 200320.33—42.14B2.07B
FY200231 Dec 200223.95—42.16B1.76B
FY200131 Dec 200130.90—48.98B1.59B
FY200031 Dec 200046.91—46.21B985.00M
FY199931 Dec 199969.19—43.24B625.00M

Figures in EUR. A quarter's revenue, net income and dividends are those of its last four quarters. A forecast year's P/E is today's price over the analysts' EPS estimate for that year.

See also:Market cap,P/S ratio,ROE (return on equity),Debt to equity,Current ratio,All ratios

Common questions about Sanofi ADS's P/E ratio

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.